SAN FRANCISCO — A San Mateo County jury has hit Swiss pharmaceutical company Actelion with a $547 million verdict after finding the company interfered with the development of a hypertension drug by a Japanese company.

The jury on Friday also found Actelion and other defendants acted with malice and is set to deliberate Tuesday on punitive damages.